DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices.
Clinical Trials for: aprepitant
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Status: Recruiting Condition: Chemotherapy Induced Nausea and Vomiting
Efficacy of Aprepitant (Emend®) in Children
Status: Not yet recruiting Condition: Nausea; Vomiting; Childhood Cancer
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3)
Status: Recruiting Condition: Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)(COMPLETED)
Status: Completed Condition: Chemotherapy-Induced Nausea and Vomiting (CINV)
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3)
Status: Recruiting Condition: Chemotherapy-induced Nausea and Vomiting
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
Status: Completed Condition: Lymphoma
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
Status: Recruiting Condition: Cancer; Malignancy
Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
Status: Not yet recruiting Condition: Nausea; Vomiting
Re-examination Study of EMEND (Aprepitant) (MK-0869-184 AM1)
Status: Completed Condition: Chemotherapy-induced Nausea and Vomiting
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Patented / Exclusive Use|
|CAPSULE; ORAL||021549||Mar 26, 2003||RX||No||<disabled>||LABELING REVISIONS RELATED TO CLINICAL STUDIES|
|CAPSULE; ORAL||021549||Mar 26, 2003||RX||No||5,538,982||<disabled>||TREATMENT OR PREVENTION OF EMESIS|
|CAPSULE; ORAL||021549||Mar 26, 2003||RX||No||8,258,132||Y||<disabled>||PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING|
|CAPSULE; ORAL||021549||Mar 26, 2003||RX||No||8,258,132||Y||<disabled>||PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639`abc